Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.45 USD
Change Today +0.1709 / 7.50%
Volume 293.0K
OGEN On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 3:43 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Open
$2.34
Previous Close
$2.28
Day High
$2.93
Day Low
$2.30
52 Week High
08/6/15 - $3.87
52 Week Low
06/2/15 - $0.66
Market Cap
90.1M
Average Volume 10 Days
200.5K
EPS TTM
$-0.27
Shares Outstanding
36.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. develops, markets, and sells oral probiotics products and antibiotics for humans and companion pets. The company develops and markets probiotic products comprising ProBiora3, ProBiora3, a blend of oral care probiotics that promote fresher breath, whiter teeth, and support oral health under the Evora and ProBiora brands. Its ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. The company’s products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140 and other homolog antibiotic products. The company markets and sells its products through direct-to-consumer channels, professional offices, and private label partnerships. It has collaboration agreement with Intrexon Corporation for the development and commercialization of the native strain of MU1140 and related homologs. The company, formerly known as Oragen, Inc., was founded in 1996 and is headquartered in Tampa, Florida.

12 Employees
Last Reported Date: 02/27/15
Founded in 1996

oragenics inc (OGEN) Top Compensated Officers

Interim Principal Executive Officer, Chief Fi...
Total Annual Compensation: $220.7K
Senior Vice President of Operations & Product...
Total Annual Compensation: $188.9K
Senior Vice President of Discovery Research
Total Annual Compensation: $194.1K
Compensation as of Fiscal Year 2014.

oragenics inc (OGEN) Key Developments

Oragenics, Inc. Reports Positive in Vivo Antibiotic Efficacy Data in Critical Animal Study

Oragenics Inc. and Intrexon Corporation announced positive data on multiple compounds from Oragenics’ Mutacin 1140 (MU1140) lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate. The compounds were subjected to a standardized ‘proof of concept’ animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomycin positive control. Lantibiotics are a class of antibiotics with a novel mechanism of action active against several multi-drug resistant infectious agents. Through its Exclusive Channel Collaboration (ECC), Oragenics has utilized Intrexon’s proprietary bio-engineering capabilities to develop its MU1140 analog pipeline which could provide an important new tool in the fight against global bacterial antibiotic resistance. The tested compounds were selected based on important compound characteristics including, but not limited to: drug activity (based on minimum inhibitory concentration) equal or better than ‘standard of care’ drugs against certain drug-resistant bacteria, safety, toxicity, stability, and manufacturability. The study specifically evaluated compound efficacy as measured by survivability, amounts of C. difficile colony forming units, and toxin levels. Overall several compounds demonstrated promising results, and Oragenics’ new lead clinical candidate achieved a 100% survival rate throughout the entire study in contrast to a 33% survival rate for the vancomycin (current standard of care) positive control. There was a 0% survival rate for the placebo control group.

Intrexon Corporation and Oragenics Announce Exclusive Channel Collaboration

Intrexon Corporation and Oragenics announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. Under the terms of the agreement, Oragenics will have access to Intrexon's technologies and expertise to develop products for the treatment of oral mucositis or products containing genetically modified Lactococcus lactis expressing trefoil factors in the oral cavity, throat, and esophagus for a technology access fee and will reimburse Intrexon for the research and development costs. The agreement also provides for commercial and regulatory milestone payments to Intrexon, as well as a low double-digit percentage royalty based on the net sales from collaboration products.

Oragenics Inc., Annual General Meeting, Jul 16, 2015

Oragenics Inc., Annual General Meeting, Jul 16, 2015., at 09:00 US Eastern Standard Time. Location: Grand Hyatt Tampa Bay. Agenda: To re-elect five Directors of the company to serve until the next annual meeting of shareholders; to conduct a non-binding advisory vote on executive compensation; to ratify the selection of Mayer Hoffman McCann P.C. as the company's independent auditors for the year ending December 31, 2015; and to transact such other business as may properly come before the annual meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $2.45 USD +0.1709

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr271.50 SEK +1.50
BLIS Technologies Ltd $0.02 NZD +0.002
View Industry Companies
 

Industry Analysis

OGEN

Industry Average

Valuation OGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.7x
Price/Book 26.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAGENICS INC, please visit www.oragenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.